CARE ACCESS RESEARCH
- Type
- Non-covered entity
- Where
- BOSTON, MA
- Received
- $4,644,745 in 479 records, 2019 to 2025 ($0 general, $4,644,745 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Care Access Research LLC Fuzzy (name and state)
- Business registration: Care Access Research LLC Fuzzy (name and state)
- Business registration: Care Access Research LLC Fuzzy (name and state)
- Business registration: Care Access Research LLC Fuzzy (name and state)
- Business registration: Care Access Research LLC Fuzzy (name and state)
- Business registration: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Business registration: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Business registration: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Business registration: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Business registration: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Plan sponsor: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Federal award recipient: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
- Trademark owner: CARE ACCESS RESEARCH LLC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 102 | $1,362,430 |
| 2024 | Research payment | 69 | $1,709,330 |
| 2023 | Research payment | 48 | $1,064,590 |
| 2022 | Research payment | 40 | $261,693 |
| 2021 | Research payment | 197 | $189,690 |
| 2020 | Research payment | 13 | $45,199 |
| 2019 | Research payment | 10 | $11,810 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 76 | $1,877,526 | 2021–2025 |
| Celgene Corporation | 28 | $1,301,172 | 2022–2025 |
| Novartis Pharmaceuticals Corporation | 34 | $672,123 | 2021–2025 |
| GlaxoSmithKline, LLC. | 73 | $397,130 | 2022–2025 |
| AstraZeneca UK Limited | 3 | $94,016 | 2021–2025 |
| ABBVIE INC. | 40 | $84,880 | 2022–2025 |
| E.R. Squibb & Sons, L.L.C. | 8 | $84,487 | 2023–2025 |
| IRONWOOD PHARMACEUTICALS, INC | 30 | $39,226 | 2020–2021 |
| Novo Nordisk AS | 163 | $27,645 | 2021 |
| UCB SA | 9 | $18,754 | 2021–2022 |
| Mirati Therapeutics, Inc. | 1 | $17,875 | 2024 |
| PFIZER INC. | 1 | $16,788 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $11,810 | 2019 |
| Allergan, Inc. | 3 | $1,307 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 479 | $4,644,745 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | GlaxoSmithKline, LLC. | $924 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-12-19 | GlaxoSmithKline, LLC. | $556 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | 2025 | |
| 2025-12-12 | GlaxoSmithKline, LLC. | $845 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-12-05 | GlaxoSmithKline, LLC. | $215 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | 2025 | |
| 2025-12-03 | AstraZeneca Pharmaceuticals LP | $20,650 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-12-03 | AstraZeneca Pharmaceuticals LP | $17,350 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-12-01 | Novartis Pharmaceuticals Corporation | $1,067 | Research payment | In-kind items and services | ADAKVEO Drug, Hematology | A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu | 2025 |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $6,676 | Research payment | Cash or cash equivalent | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 | |
| 2025-11-25 | GlaxoSmithKline, LLC. | $9,268 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-11-21 | GlaxoSmithKline, LLC. | $23,185 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-11-21 | GlaxoSmithKline, LLC. | $7,662 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | $6,293 | Research payment | Cash or cash equivalent | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 | |
| 2025-11-12 | E.R. Squibb & Sons, L.L.C. | $5,750 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | 2025 |
| 2025-11-12 | GlaxoSmithKline, LLC. | $26 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-10-30 | Novartis Pharmaceuticals Corporation | $18,500 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Effi | 2025 | |
| 2025-10-29 | GlaxoSmithKline, LLC. | $13,500 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | 2025 | |
| 2025-10-29 | GlaxoSmithKline, LLC. | $2,500 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | 2025 | |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | $18,806 | Research payment | Cash or cash equivalent | SCEMBLIX Drug, Oncology | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2025 |
| 2025-10-23 | GlaxoSmithKline, LLC. | $11,737 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-10-23 | GlaxoSmithKline, LLC. | $5,711 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-10-17 | GlaxoSmithKline, LLC. | $5,926 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-10-09 | GlaxoSmithKline, LLC. | $313 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-10-06 | Novartis Pharmaceuticals Corporation | $19,030 | Research payment | In-kind items and services | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 | |
| 2025-10-02 | GlaxoSmithKline, LLC. | $7,760 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-10-02 | GlaxoSmithKline, LLC. | $260 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-09-24 | GlaxoSmithKline, LLC. | $19,008 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-09-24 | GlaxoSmithKline, LLC. | $5,661 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-09-24 | GlaxoSmithKline, LLC. | $556 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $21,400 | Research payment | Cash or cash equivalent | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Densit | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20,650 | Research payment | Cash or cash equivalent | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Densit | 2025 | |
| 2025-09-05 | GlaxoSmithKline, LLC. | $278 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-09-04 | Novartis Pharmaceuticals Corporation | $3,751 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-09-03 | GlaxoSmithKline, LLC. | $12,311 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-09-03 | GlaxoSmithKline, LLC. | $1,492 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-09-03 | GlaxoSmithKline, LLC. | $823 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-09-03 | GlaxoSmithKline, LLC. | $278 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-08-26 | Novartis Pharmaceuticals Corporation | $4,500 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-08-22 | GlaxoSmithKline, LLC. | $30,460 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $20,650 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $20,650 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $17,350 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-08-14 | GlaxoSmithKline, LLC. | $37,284 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-14 | Novartis Pharmaceuticals Corporation | $28 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-08-08 | GlaxoSmithKline, LLC. | $558 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $23,452 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 | |
| 2025-08-07 | GlaxoSmithKline, LLC. | $173 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-06 | Celgene Corporation | $655 | Research payment | Cash or cash equivalent | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 | |
| 2025-08-06 | GlaxoSmithKline, LLC. | $563 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-06 | GlaxoSmithKline, LLC. | $62 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-04 | GlaxoSmithKline, LLC. | $1,113 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-08-01 | GlaxoSmithKline, LLC. | $12,430 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-08-01 | GlaxoSmithKline, LLC. | $834 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $46,465 | Research payment | Cash or cash equivalent | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Densit | 2025 | |
| 2025-07-30 | AstraZeneca UK Limited | $20,084 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and | 2025 |
| 2025-07-23 | AstraZeneca Pharmaceuticals LP | $21,400 | Research payment | Cash or cash equivalent | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combi | 2025 | |
| 2025-07-23 | GlaxoSmithKline, LLC. | $1,257 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-07-23 | GlaxoSmithKline, LLC. | $810 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-07-18 | GlaxoSmithKline, LLC. | $5,711 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $11,863 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $10,849 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $556 | Research payment | Cash or cash equivalent | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-06-20 | GlaxoSmithKline, LLC. | $2,766 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-06-06 | GlaxoSmithKline, LLC. | $7 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-06-02 | GlaxoSmithKline, LLC. | $31 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-05-21 | GlaxoSmithKline, LLC. | $2,115 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-05-14 | AstraZeneca Pharmaceuticals LP | $12,804 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-04-03 | Novartis Pharmaceuticals Corporation | $616 | Research payment | In-kind items and services | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-03-14 | AstraZeneca Pharmaceuticals LP | $3,652 | Research payment | Cash or cash equivalent | A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozi | 2025 | |
| 2025-03-13 | ABBVIE INC. | $120 | Research payment | Cash or cash equivalent | ANDROGEL Drug, ENDOCRINOLOGY | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2025 |
| 2025-03-13 | ABBVIE INC. | $41 | Research payment | Cash or cash equivalent | ANDROGEL Drug, ENDOCRINOLOGY | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2025 |
| 2025-03-13 | ABBVIE INC. | $28 | Research payment | Cash or cash equivalent | ANDROGEL Drug, ENDOCRINOLOGY | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2025 |
| 2025-02-26 | Celgene Corporation | $20,500 | Research payment | Cash or cash equivalent | A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to | 2025 | |
| 2025-02-25 | GlaxoSmithKline, LLC. | $924 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-02-14 | Celgene Corporation | $26,827 | Research payment | Cash or cash equivalent | A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected | 2025 | |
| 2025-02-07 | Celgene Corporation | $9,992 | Research payment | Cash or cash equivalent | A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to | 2025 | |
| 2025-02-06 | GlaxoSmithKline, LLC. | $221 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-01-30 | GlaxoSmithKline, LLC. | $12,462 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-01-30 | GlaxoSmithKline, LLC. | $692 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-01-29 | AstraZeneca Pharmaceuticals LP | $64,302 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-29 | AstraZeneca Pharmaceuticals LP | $11,263 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-29 | AstraZeneca Pharmaceuticals LP | $4,573 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-24 | AstraZeneca Pharmaceuticals LP | $26,250 | Research payment | Cash or cash equivalent | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,pl | 2025 | |
| 2025-01-24 | GlaxoSmithKline, LLC. | $1,378 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $44,477 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $27,062 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $24,332 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $23,300 | Research payment | Cash or cash equivalent | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $18,500 | Research payment | Cash or cash equivalent | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $15,829 | Research payment | Cash or cash equivalent | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $12,939 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 | |
| 2025-01-21 | Novartis Pharmaceuticals Corporation | $12,000 | Research payment | Cash or cash equivalent | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 | 2025 | |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | $18,749 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2025 |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | $13,388 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2025 |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | $8,999 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2025 |
| 2025-01-13 | Celgene Corporation | $76,432 | Research payment | Cash or cash equivalent | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 | |
| 2025-01-13 | Celgene Corporation | $26,390 | Research payment | Cash or cash equivalent | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 | |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $149,583 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $36,967 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $25,730 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $18,287 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $13,942 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-10 | AstraZeneca Pharmaceuticals LP | $13,460 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2024-12-19 | GlaxoSmithKline, LLC. | $12,462 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2024 |
| 2024-12-16 | Novartis Pharmaceuticals Corporation | $8,455 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-11-27 | Novartis Pharmaceuticals Corporation | $20,098 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-11-06 | Mirati Therapeutics, Inc. | $17,875 | Research payment | Cash or cash equivalent | KRAZATI Drug, Oncology | A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combi | 2024 |
| 2024-10-28 | Novartis Pharmaceuticals Corporation | $6,500 | Research payment | Cash or cash equivalent | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 | 2024 | |
| 2024-10-23 | GlaxoSmithKline, LLC. | $2,493 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-10-04 | GlaxoSmithKline, LLC. | $124 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-25 | GlaxoSmithKline, LLC. | $4,927 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-20 | GlaxoSmithKline, LLC. | $465 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-18 | GlaxoSmithKline, LLC. | $4,245 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-11 | GlaxoSmithKline, LLC. | $809 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-06 | GlaxoSmithKline, LLC. | $25 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-09-04 | Novartis Pharmaceuticals Corporation | $3,384 | Research payment | In-kind items and services | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-08-30 | Novartis Pharmaceuticals Corporation | $18,500 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-08-21 | GlaxoSmithKline, LLC. | $9,189 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $20,500 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapaglif | 2024 | |
| 2024-07-24 | GlaxoSmithKline, LLC. | $6,709 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-06-26 | AstraZeneca Pharmaceuticals LP | $46,734 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-06-26 | Novartis Pharmaceuticals Corporation | $14,404 | Research payment | Cash or cash equivalent | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-06-26 | AstraZeneca Pharmaceuticals LP | $10,376 | Research payment | Cash or cash equivalent | COSMOS - A Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability and Pharmacody | 2024 | |
| 2024-06-25 | GlaxoSmithKline, LLC. | $6,234 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-06-12 | AstraZeneca Pharmaceuticals LP | $49,762 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-06-04 | Novartis Pharmaceuticals Corporation | $8,687 | Research payment | In-kind items and services | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-05-24 | AstraZeneca Pharmaceuticals LP | $23,322 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapaglif | 2024 | |
| 2024-05-22 | GlaxoSmithKline, LLC. | $3,687 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-05-06 | Novartis Pharmaceuticals Corporation | $2,324 | Research payment | In-kind items and services | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 | |
| 2024-05-01 | GlaxoSmithKline, LLC. | $133 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-29 | Novartis Pharmaceuticals Corporation | $29,041 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-04-22 | GlaxoSmithKline, LLC. | $1,451 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-19 | GlaxoSmithKline, LLC. | $7,276 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-17 | GlaxoSmithKline, LLC. | $119 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-05 | GlaxoSmithKline, LLC. | $4,000 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-01 | Novartis Pharmaceuticals Corporation | $94,110 | Research payment | Cash or cash equivalent | SCEMBLIX Drug, Oncology | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2024 |
| 2024-03-27 | AstraZeneca Pharmaceuticals LP | $7,500 | Research payment | Cash or cash equivalent | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2024 | |
| 2024-03-25 | GlaxoSmithKline, LLC. | $36,445 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-03-22 | GlaxoSmithKline, LLC. | $9,000 | Research payment | Cash or cash equivalent | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-03-20 | AstraZeneca Pharmaceuticals LP | $99,613 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2024 |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $74,313 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $49,032 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $32,640 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $30,224 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-03-06 | AstraZeneca Pharmaceuticals LP | $15,391 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2024 |
| 2024-02-21 | GlaxoSmithKline, LLC. | $3,821 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-02-21 | AstraZeneca Pharmaceuticals LP | $2,000 | Research payment | Cash or cash equivalent | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and | 2024 | |
| 2024-02-16 | AstraZeneca Pharmaceuticals LP | $4,500 | Research payment | Cash or cash equivalent | This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active compara | 2024 | |
| 2024-02-16 | GlaxoSmithKline, LLC. | $284 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-02-14 | AstraZeneca Pharmaceuticals LP | $128,381 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-02-14 | AstraZeneca Pharmaceuticals LP | $31,253 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-02-12 | Celgene Corporation | $130,137 | Research payment | Cash or cash equivalent | Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extensi | 2024 | |
| 2024-02-12 | Celgene Corporation | $39,932 | Research payment | Cash or cash equivalent | Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extensi | 2024 | |
| 2024-02-12 | Celgene Corporation | $4,970 | Research payment | Cash or cash equivalent | Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extensi | 2024 | |
| 2024-02-02 | AstraZeneca Pharmaceuticals LP | $23,474 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-02-02 | Celgene Corporation | $17,350 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2024 | |
| 2024-02-02 | AstraZeneca Pharmaceuticals LP | $6,340 | Research payment | Cash or cash equivalent | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and | 2024 | |
| 2024-02-02 | GlaxoSmithKline, LLC. | $2,983 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-02-01 | E.R. Squibb & Sons, L.L.C. | $35,083 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Bioma | 2024 |
| 2024-01-31 | AstraZeneca Pharmaceuticals LP | $20,000 | Research payment | Cash or cash equivalent | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generatio | 2024 | |
| 2024-01-31 | Celgene Corporation | $5,000 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2024 | |
| 2024-01-29 | Novartis Pharmaceuticals Corporation | $84,274 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-26 | E.R. Squibb & Sons, L.L.C. | $4,175 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | 2024 |
| 2024-01-24 | AstraZeneca Pharmaceuticals LP | $38,004 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-01-24 | GlaxoSmithKline, LLC. | $1,823 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-01-17 | AstraZeneca Pharmaceuticals LP | $53,754 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2024 |
| 2024-01-12 | Celgene Corporation | $56,205 | Research payment | Cash or cash equivalent | Phase 1 Drug Interaction (AKA IM042-002) (EOE) | 2024 | |
| 2024-01-08 | Novartis Pharmaceuticals Corporation | $83,175 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-05 | AstraZeneca Pharmaceuticals LP | $10,576 | Research payment | Cash or cash equivalent | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and | 2024 | |
| 2024-01-03 | Celgene Corporation | $61,967 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2024 | |
| 2024-01-03 | Celgene Corporation | $37,956 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2024 | |
| 2024-01-03 | Celgene Corporation | $29,315 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2024 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $2,036 | Research payment | In-kind items and services | EVUSHELD Drug, Vaccines & Immune Therapies | AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD whic | 2023 |
| 2023-12-29 | Novartis Pharmaceuticals Corporation | $35,985 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-12-11 | Celgene Corporation | $53,490 | Research payment | Cash or cash equivalent | Phase 1 Drug Interaction (AKA IM042-002) (EOE) | 2023 | |
| 2023-11-16 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-11-16 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-11-15 | E.R. Squibb & Sons, L.L.C. | $5,700 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Peri | 2023 |
| 2023-11-07 | ABBVIE INC. | $2,438 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-10-06 | Celgene Corporation | $17,146 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2023 | |
| 2023-10-06 | Celgene Corporation | $14,912 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2023 | |
| 2023-09-05 | ABBVIE INC. | $2,438 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-08-09 | Celgene Corporation | $14,500 | Research payment | Cash or cash equivalent | Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extensi | 2023 | |
| 2023-08-03 | ABBVIE INC. | $4,361 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-08-01 | E.R. Squibb & Sons, L.L.C. | $15,000 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Bioma | 2023 |
| 2023-07-28 | AstraZeneca Pharmaceuticals LP | $1,250 | Research payment | Cash or cash equivalent | This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active compara | 2023 | |
| 2023-07-14 | E.R. Squibb & Sons, L.L.C. | $5,809 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | 2023 |
| 2023-07-07 | AstraZeneca Pharmaceuticals LP | $19,000 | Research payment | Cash or cash equivalent | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generatio | 2023 | |
| 2023-07-06 | ABBVIE INC. | $2,188 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-06-14 | Celgene Corporation | $55,129 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2023 | |
| 2023-05-17 | AstraZeneca Pharmaceuticals LP | $20,943 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-05-10 | AstraZeneca Pharmaceuticals LP | $15,450 | Research payment | Cash or cash equivalent | This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active compara | 2023 | |
| 2023-05-04 | ABBVIE INC. | $4,085 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2023 |
| 2023-04-28 | AstraZeneca Pharmaceuticals LP | $15,000 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-28 | AstraZeneca Pharmaceuticals LP | $15,000 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-28 | AstraZeneca Pharmaceuticals LP | $15,000 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-26 | AstraZeneca Pharmaceuticals LP | $20,943 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-26 | AstraZeneca Pharmaceuticals LP | $17,000 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-26 | AstraZeneca Pharmaceuticals LP | $15,000 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and F | 2023 |
| 2023-04-19 | ABBVIE INC. | $4,000 | Research payment | Cash or cash equivalent | ANDROGEL Drug, ENDOCRINOLOGY | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2023 |
| 2023-04-14 | AstraZeneca Pharmaceuticals LP | $16,850 | Research payment | Cash or cash equivalent | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and | 2023 |
The latest 200 records of 479.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments